BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 20471663)

  • 1. Clonal analysis of bilateral, recurrent, and metastatic papillary thyroid carcinomas.
    Wang W; Wang H; Teng X; Wang H; Mao C; Teng R; Zhao W; Cao J; Fahey TJ; Teng L
    Hum Pathol; 2010 Sep; 41(9):1299-309. PubMed ID: 20471663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BRAF mutational analysis in papillary carcinomas with mixed follicular and papillary growth patterns.
    Jakubowski M; Hunt JL
    Am J Surg Pathol; 2009 Nov; 33(11):1590-3. PubMed ID: 19738460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular evidence for the same clonal origin of multifocal papillary thyroid carcinomas.
    McCarthy RP; Wang M; Jones TD; Strate RW; Cheng L
    Clin Cancer Res; 2006 Apr; 12(8):2414-8. PubMed ID: 16638846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRAF(V600E) mutation analysis of liquid-based preparation-processed fine needle aspiration sample improves the diagnostic rate of papillary thyroid carcinoma.
    Chang H; Lee H; Yoon SO; Kim H; Kim A; Kim BH
    Hum Pathol; 2012 Jan; 43(1):89-95. PubMed ID: 21774961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [An investigation of BRAF mutation in papillary thyroid carcinoma and its clinical value].
    Gong RX; Zhou Y; Luo SH; Zhang L; Zhou B
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2009 Jun; 26(3):310-3. PubMed ID: 19504446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Most multifocal papillary thyroid carcinomas acquire genetic and morphotype diversity through subclonal evolution following the intra-glandular spread of the initial neoplastic clone.
    Jovanovic L; Delahunt B; McIver B; Eberhardt NL; Grebe SK
    J Pathol; 2008 Jun; 215(2):145-54. PubMed ID: 18393366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutational analysis of metastatic lymph nodes from papillary thyroid carcinoma in adult and pediatric patients.
    Shifrin AL; Fischer M; Paul T; Erler B; Gheysens K; Baodhankar P; Song-Yang JW; Taylor S; Timmaraju VA; Topilow A; Mireskandari A; Kumar G
    Surgery; 2017 Jan; 161(1):176-187. PubMed ID: 27866718
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BRAF V600E mutation and p27 kip1 expression in papillary carcinomas of the thyroid Rodolico V; Cabibi D; Pizzolanti G; Richiusa P; Gebbia N; Martorana A; Russo A; Amato MC; Galluzzo A; Giordano C
    Cancer; 2007 Sep; 110(6):1218-26. PubMed ID: 17685465
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular genetic evidence for the independent origin of multifocal papillary tumors in patients with papillary renal cell carcinomas.
    Jones TD; Eble JN; Wang M; MacLennan GT; Delahunt B; Brunelli M; Martignoni G; Lopez-Beltran A; Bonsib SM; Ulbright TM; Zhang S; Nigro K; Cheng L
    Clin Cancer Res; 2005 Oct; 11(20):7226-33. PubMed ID: 16243792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clonal origin of lymph node metastases in bladder carcinoma.
    Jones TD; Carr MD; Eble JN; Wang M; Lopez-Beltran A; Cheng L
    Cancer; 2005 Nov; 104(9):1901-10. PubMed ID: 16196038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimizing surgical treatment of papillary thyroid carcinoma associated with BRAF mutation.
    Yip L; Nikiforova MN; Carty SE; Yim JH; Stang MT; Tublin MJ; Lebeau SO; Hodak SP; Ogilvie JB; Nikiforov YE
    Surgery; 2009 Dec; 146(6):1215-23. PubMed ID: 19958951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of the T1799A BRAF mutation with tumor extrathyroidal invasion, higher peripheral platelet counts, and over-expression of platelet-derived growth factor-B in papillary thyroid cancer.
    Wang Y; Ji M; Wang W; Miao Z; Hou P; Chen X; Xu F; Zhu G; Sun X; Li Y; Condouris S; Liu D; Yan S; Pan J; Xing M
    Endocr Relat Cancer; 2008 Mar; 15(1):183-90. PubMed ID: 18310286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multicentric occurrence of multiple papillary thyroid carcinomas--HUMARA and BRAF mutation analysis.
    Nakazawa T; Kondo T; Tahara I; Kasai K; Inoue T; Oishi N; Mochizuki K; Kubota T; Katoh R
    Cancer Med; 2015 Aug; 4(8):1272-80. PubMed ID: 25882744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Poorer prognosis and higher prevalence of BRAF (V600E) mutation in synchronous bilateral papillary thyroid carcinoma.
    Wang W; Zhao W; Wang H; Teng X; Wang H; Chen X; Li Z; Yu X; Fahey TJ; Teng L
    Ann Surg Oncol; 2012 Jan; 19(1):31-6. PubMed ID: 22033631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma.
    Kim TY; Kim WB; Rhee YS; Song JY; Kim JM; Gong G; Lee S; Kim SY; Kim SC; Hong SJ; Shong YK
    Clin Endocrinol (Oxf); 2006 Sep; 65(3):364-8. PubMed ID: 16918957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Both BRAF V600E mutation and older age (≥ 65 years) are associated with recurrent papillary thyroid cancer.
    Howell GM; Carty SE; Armstrong MJ; Lebeau SO; Hodak SP; Coyne C; Stang MT; McCoy KL; Nikiforova MN; Nikiforov YE; Yip L
    Ann Surg Oncol; 2011 Dec; 18(13):3566-71. PubMed ID: 21594703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The heterogeneous distribution of BRAF mutation supports the independent clonal origin of distinct tumor foci in multifocal papillary thyroid carcinoma.
    Giannini R; Ugolini C; Lupi C; Proietti A; Elisei R; Salvatore G; Berti P; Materazzi G; Miccoli P; Santoro M; Basolo F
    J Clin Endocrinol Metab; 2007 Sep; 92(9):3511-6. PubMed ID: 17535994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lymphatic mapping establishes the role of BRAF gene mutation in papillary thyroid carcinoma.
    Kim J; Giuliano AE; Turner RR; Gaffney RE; Umetani N; Kitago M; Elashoff D; Hoon DS
    Ann Surg; 2006 Nov; 244(5):799-804. PubMed ID: 17060774
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BRAF, p53 and SOX2 in anaplastic thyroid carcinoma: evidence for multistep carcinogenesis.
    Gauchotte G; Philippe C; Lacomme S; Léotard B; Wissler MP; Allou L; Toussaint B; Klein M; Vignaud JM; Bressenot A
    Pathology; 2011 Aug; 43(5):447-52. PubMed ID: 21716161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical significance of BRAF (V600E) mutation and Ki-67 labeling index in papillary thyroid carcinomas.
    Nakayama H; Yoshida A; Nakamura Y; Hayashi H; Miyagi Y; Wada N; Rino Y; Masuda M; Imada T
    Anticancer Res; 2007; 27(5B):3645-9. PubMed ID: 17972530
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.